Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
17 Janvier 2024 - 2:05PM
Business Wire
COSMOS study shows Guardant Reveal™ blood test highly predictive
for disease recurrence in patients with early-stage colon cancer
without need for tissue specimen
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, will present interim data from the COSMOS study supporting
the use of Guardant Reveal to predict disease recurrence in
patients with early-stage colon cancer at the ASCO 2024
Gastrointestinal Cancers Symposium, January 18-20 in San
Francisco.
Guardant Reveal analyzes comprehensive molecular signals in the
blood to detect and quantify minimal residual disease (MRD). The
COSMOS study evaluated the use of the newest version of the test,
built on the Guardant Infinity™ smart liquid biopsy platform, to
identify MRD and predict disease recurrence in 130 patients with
early-stage (II and III) colon cancer. Interim data to be shared at
ASCO GI suggest the test is both highly specific (low false
positives) and predictive for recurrence, without dependence on a
tissue sample.
“Studies have established the presence of residual disease after
surgery is associated with a higher probability of recurrence in
early-stage colon cancer,” said Craig Eagle, M.D., Guardant Health
chief medical officer. “The interim COSMOS data are very promising
and support the use of Guardant Reveal to predict disease
recurrence and help inform adjuvant therapy decisions for patients
with Stage II or III colon cancer.”
Guardant and its research partners will also present multiple
posters at the symposium highlighting the application of Guardant
technology in blood-based screening and in identifying potentially
targetable mutations in GI cancers, including predictive markers
for treatment resistance.
Guardant Health 2024 ASCO GI Poster Presentations
Guardant Reveal
- Multiomic Analysis for Minimal Residual Disease Detection:
Addressing Challenges in Stage II-III Colon Cancer from
COSMOS-CRC-01 (Abstract 180 | Poster Bd L8)
- Early Identification and Treatment of Occult Metastatic Disease
in Stage III Colon Cancer (ACT3) (Abstract 148 | Poster Bd
J14)
- Phase II results of Circulating tumOr DNA as a predictive
BiomaRker in Adjuvant chemotherapy in patients with stage II colon
cancer: NRG-GI005 (COBRA) Phase II/III Study (Oral Abstract
Session; Abstract 5)
Guardant360®
- The genomic landscape of advanced colorectal adenocarcinoma
patients with PIK3CA mutations using comprehensive cell free tumor
DNA next generation sequencing (Abstract 181 | Poster Bd L9)
- Association of candidate alterations with primary resistance to
KRAS G12D targeting in colorectal cancer (Abstract 170 | Poster Bd
K18)
GuardantINFORM™
- Clinical utility of serial circulating tumor DNA (ctDNA) to
identify acquired resistance to anti-EGFR antibodies in metastatic
colorectal cancer (mCRC) (Abstract 158 | Poster Bd K6)
- Real-world testing and treatment patterns and outcomes
following liquid biopsy in advanced cholangiocarcinoma (Abstract
455 | Poster Bd A20)
- Assessment of circulating tumor DNA (ctDNA) burden and
association with outcomes in metastatic gastric cancer (mGC)
patients using real-world data (RWD) (Abstract 276 | Poster Bd
C14)
Shield™
- Enhanced blood-based colorectal cancer screening with improved
performance in detection of early stage disease (Abstract 68 |
Poster Bd E11)
- Circulating tumor DNA (ctDNA) positivity and its association
with clinicopathological characteristics by novel blood-based test
for colorectal cancer (CRC) screening from a multi-center large
cohort: COSMOS-CRC-01 (Abstract 69 | Poster Bd E12)
- Prospective study of a multi-modal blood-based test for
colorectal cancer screening (Abstract 70 | Poster Bd E13)
The full abstracts are available on the official ASCO 2024 GI
Cancers Symposium website.
About Guardant Health
Guardant Health is a leading precision oncology company focused
on guarding wellness and giving every person more time free from
cancer. Founded in 2012, Guardant is transforming patient care by
providing critical insights into what drives disease through its
advanced blood and tissue tests, real-world data and AI analytics.
Guardant tests help improve outcomes across all stages of care,
including screening to find cancer early, monitoring for recurrence
in early-stage cancer, and helping doctors select the best
treatment for patients with advanced cancer. For more information,
visit guardanthealth.com and follow the company on LinkedIn, X
(Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2022, and any
current and periodic reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking
statements in this press release are based on information available
to Guardant Health as of the date hereof, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240117367538/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Michael Weist press@guardanthealth.com +1
650-647-3643
Guardant Health (NASDAQ:GH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Guardant Health (NASDAQ:GH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024